Titre : The Liver Meeting® 2017 - Vets with HCV Might Settle Cancer Controversy
link : The Liver Meeting® 2017 - Vets with HCV Might Settle Cancer Controversy
The Liver Meeting® 2017 - Vets with HCV Might Settle Cancer Controversy
Vets with HCV Might Settle Cancer ControversyVA experience seems to rule out possible cancer-causing effect of new drugs
by Michael Smith Michael Smith, North American Correspondent, MedPage Today
October 23, 2017
WASHINGTON -- Analysis of America's veterans might have closed the books on a controversy over modern hepatitis C (HCV) treatment.
In the largest cohort analyzed to date -- some 62,000 patients in the VA system -- there is no evidence that therapy with newer agents that act directly against the virus (DAAs) increases the risk of hepatocellular carcinoma (HCC), according to George Ioannou, BMBCh, of the Veterans Affairs Puget Sound Health Care System in Seattle.
In fact, curing HCV with the DAAs is associated with a 71% reduction in the risk of HCC -- much the same picture seen after a cure with earlier regimens, Ioannou told reporters at the Liver Meeting, the annual conference of the American Association for the Study of Liver Diseases.
Read the article at MedPage Today.
MedPage Today - American Association for the Study of Liver Diseases
Meeting Coverage
AASLD Press Release
The Liver Meeting® - Direct‐Acting Antiviral Therapy Cuts Liver Cancer Risk By 71%
Navigate This Blog
The Liver Meeting® 2017
Patient-Friendly Links
HCV Sites With Key Data, Expert Review & Summary
In the largest cohort analyzed to date -- some 62,000 patients in the VA system -- there is no evidence that therapy with newer agents that act directly against the virus (DAAs) increases the risk of hepatocellular carcinoma (HCC), according to George Ioannou, BMBCh, of the Veterans Affairs Puget Sound Health Care System in Seattle.
In fact, curing HCV with the DAAs is associated with a 71% reduction in the risk of HCC -- much the same picture seen after a cure with earlier regimens, Ioannou told reporters at the Liver Meeting, the annual conference of the American Association for the Study of Liver Diseases.
Read the article at MedPage Today.
MedPage Today - American Association for the Study of Liver Diseases
Meeting Coverage
AASLD Press Release
The Liver Meeting® - Direct‐Acting Antiviral Therapy Cuts Liver Cancer Risk By 71%
Navigate This Blog
The Liver Meeting® 2017
Patient-Friendly Links
HCV Sites With Key Data, Expert Review & Summary
Thus articles The Liver Meeting® 2017 - Vets with HCV Might Settle Cancer Controversy
that is all articles The Liver Meeting® 2017 - Vets with HCV Might Settle Cancer Controversy This time, hopefully can provide benefits to you all. Okay, see you in another article post.
You are now reading the article The Liver Meeting® 2017 - Vets with HCV Might Settle Cancer Controversy the link address https://newsaninpiration.blogspot.com/2017/10/the-liver-meeting-2017-vets-with-hcv.html
0 Response to "The Liver Meeting® 2017 - Vets with HCV Might Settle Cancer Controversy"
Post a Comment